Latest revenue
$589.2M
as of 2026-04-03
Latest net income
$-8.8M
as of 2026-04-03
Net margin
-1.5%
as of 2026-04-03
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.39B
- Enterprise value
- $1.39B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $36.82
- 52-wk low
- $21.00
- Beta
- —
- Shares out
- 57.6M
5-year trend
What this company does
Item 1. Business General Enovis Corporation (the “Company”, “Enovis”, “we” or “us”) is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion. We seek to leverage our Enovis Growth Excellence business system…
AI summary unavailable — showing raw filing excerpt
Generated from ENOV's filing dated 2026-02-26
Key risks
Item 1A. Risk Factors An investment in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with the information included elsewhere in this Form 10-K and other documents we file with the SEC. The risks and uncertainties described below are those that we have identified as material, but may not be the only risks to which Enovis might be exposed. Additional risks and uncertainties, which are currently unknown to us or that we do not currently consider to be material, may materially affect the business of Enovis and could have material adverse effects on our business, financial condition and results of operations.…
AI summary unavailable — showing raw filing excerpt
Generated from ENOV's filing dated 2026-02-26
Profitability
Gross margin
59.8%
6.8%Operating margin
-50.0%
35.9%Net margin
-52.7%
34.5%Return on equity
-79.5%
146.8%Return on assets
-30.9%
76.6%Leverage
Debt / equity
1.57×
87.0%Long-term debt / equity
0.85×
65.7%Debt / assets
61.2%
33.8%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q2 2026 2026-04-03 | $589.2M | +5.4% | $-8.8M | +84.3% | -1.5% |
Q4 2025 2025-12-31 | $575.8M | +2.6% | $-520.6M | +26.0% | -90.4% |
Q4 2025 2025-10-03 | $548.9M | +8.6% | $-571.1M | -1712.0% | -104.1% |
Q3 2025 2025-07-04 | $564.5M | +7.5% | $-36.7M | -97.1% | -6.5% |
Q2 2025 2025-04-04 | $558.8M | +8.2% | $-56.0M | +22.3% | -10.0% |
Q4 2024 2024-12-31 | $561.0M | — | $-703.3M | — | -125.4% |
Q3 2024 2024-09-27 | $505.2M | +21.0% | $-31.5M | -994.5% | -6.2% |
Q2 2024 2024-06-28 | $525.2M | +22.6% | $-18.6M | -86.5% | -3.5% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842
Your notes
Keep private notes on ENOV — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$884.5K
Insider selling
$45.3K
Net activity
+$839.2K
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ENOV
Institutional value
$791.1M
Total shares held
35.2M
Distinct holders
155
-98 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 9.9M | $226.1M | +1.0M (+11.6%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.8M | $86.6M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.6M | $58.1M | — | New |
| 4 | DIMENSIONAL FUND ADVISORS LP | 2.5M | $57.9M | -236.0K (-8.5%) | Trimmed |
| 5 | DAVENPORT & Co LLC | 2.4M | $55.5M | -1.1K (-0.0%) | Trimmed |
| 6 | River Road Asset Management, LLC | 1.5M | $34.2M | +15.7K (+1.1%) | Added |
| 7 | Nuveen, LLC | 1.2M | $26.5M | +41.4K (+3.7%) | Added |
| 8 | Allspring Global Investments Holdings, LLC | 1.0M | $24.4M | +287.7K (+38.0%) | Added |
| 9 | PRIVATE MANAGEMENT GROUP INC | 983.4K | $22.4M | — | New |
| 10 | UBS Group AG | 821.9K | $18.7M | +123.6K (+17.7%) | Added |
| 11 | ROYCE & ASSOCIATES LP | 611.1K | $13.9M | -215.8K (-26.1%) | Trimmed |
| 12 | Tributary Capital Management, LLC | 495.1K | $11.3M | -32.6K (-6.2%) | Trimmed |
| 13 | BNP PARIBAS FINANCIAL MARKETS | 439.5K | $10.0M | -4.6K (-1.0%) | Trimmed |
| 14 | Impax Asset Management Group plc | 424.1K | $9.6M | +0 (+0.0%) | No change |
| 15 | JPMORGAN CHASE & CO | 411.7K | $8.9M | +196.3K (+91.2%) | Added |
| 16 | WELLS FARGO & COMPANY/MN | 385.6K | $8.8M | -43.4K (-10.1%) | Trimmed |
| 17 | VANGUARD FIDUCIARY TRUST CO | 371.3K | $8.4M | — | New |
| 18 | Bank of New York Mellon Corp | 324.6K | $7.4M | -12.3K (-3.7%) | Trimmed |
| 19 | PRINCIPAL FINANCIAL GROUP INC | 278.0K | $6.3M | +5.4K (+2.0%) | Added |
| 20 | ENVESTNET ASSET MANAGEMENT INC | 270.1K | $6.1M | -73.2K (-21.3%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ENOV's latest filing finishes processing.